Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Impact · against what's priced in

Corvus Pharmaceuticals sees a significant valuation catalyst from positive phase 1 data for soquelitinib in atopic dermatitis. The combination of high EASI 75 response rates and durability of effect significantly improves the drug's probability of success and commercial potential.

CRVS+0.70

No priced-in read yet

In context

The 75% EASI 75 response rate in phase 1 cohort 4, coupled with benefits persisting one month post-treatment, provides a strong clinical signal for soquelitinib's efficacy and durability in atopic dermatitis.

Read from the article alone

• biotech
• pharmaceuticals
• CRVS
• atopic dermatitis
• clinical trials
• drug development
• phase 1

Search tags